FDA Reviews Roche's Gazyva for Expanded Use in Lupus Treatment
The U.S. Food and Drug Administration (FDA) is currently reviewing Roche's Gazyva (obinutuzumab) for potential approval as a treatment for systemic lupus erythematosus (SLE), an autoimmune disease. Gazyva is already approved for treating lupus nephritis, a severe kidney inflammation associated with SLE, in both the U.S. and Europe. The FDA's review follows the ALLEGORY trial, which demonstrated that Gazyva significantly reduced disease activity in SLE patients compared to a placebo. The trial showed a 76.7% response rate in the Gazyva group versus 53.5% in the control group, with improvements in secondary endpoints such as symptom flare reduction and steroid tapering. Roche aims to position Gazyva as a new standard of care for SLE, potentially preventing kidney complications in patients. 
